Marie Zhu

CTO

Marie has more than 25 years experience in the biologics research and development area in the United States, taking on important leadership positions in Pfizer, Bristol-Myers Squibb, Xencor, Astellas Pharma and other big pharmas. She was directly involved in research and clinic development of more than 20 biologics including monoclonal antibody, fusion protein, bispecific antibody, and antibody-drug conjugate (ADCs). Orencia (CTLA4 fusion protein), Padcev (ADC), and Monjuvi (mAb) were approved by FDA in 2005, 2019, and 2020.


Marie joined RemeGen in 2019 and led the team to successfully complete the BLA application of the first ADC drug (RC48) independently developed in China within one year. Dr.Zhu received her PhD degree in biochemistry from the University of Wisconsin-Madison.